Thus, a certain amount of data has been accumulated on rituximab, but in recent years, inebilizumab, a humanized anti-CD19 monoclonal antibody, was also approved for the first time in the United States in 2020 for the treatment of neuromyelitis optica spectrum disorder, an autoimmune disease, opening a new avenue for pan-B-cell depletion therapy for autoimmune diseases (35). Here, CD19 is linked to autoimmune disease.